OPUS IP
      
 
  • Home
  • ABOUT OPUS IP
  • PROTECTION
  • IP OFFICES
  • UKIPO
  • NEWS/UPDATES
  • RECENT HEARINGS
  • PATENTS
  • TRADEMARKS
  • DESIGNS
  • UK IPEC DECISIONS
  • EPO
  • NEWS/UPDATES
  • APPEAL DECISIONS
  • G/XX DECISIONS 2010-2019
  • G/XX DECISIONS 2000-2009
  • G/XX DECISIONS 1990-2000
  • G/XX DECISIONS PRE-1990
  • J/XX APPEALS 2010-2019
  • J/XX APPEALS 2000-2009
  • J/XX APPEALS 1990-2000
  • J/XX APPEALS PRE-1990
  • T/XXXX APPEALS 2010-2019
  • T/XXXX APPEALS 2000-2009
  • T/XXXX APPEALS 1990-1999
  • T/XXXX APPEALS pre-1990
  • WIPO – PCT/MADRID/HAGUE
  • NEWS/UPDATES
  • PCT NEWSLETTER
  • PATENTS NEWS
  • TREATY MODIFICATIONS
  • MADRID SYSTEM (TM)
  • HAGUE SYSTEM (DESIGNS)
  • PATENTSCOPE/SEARCHING
  • USPTO
  • NEWS/UPDATES
  • GENERAL
  • PATENTS
  • TRADEMARKS
  • COPYRIGHT
  • EUIPO
  • NEWS/UPDATES
  • SEARCH CASES (EXTERNAL)
  • IP NEWS/LINKS
  • LINKS TO IP RESOURCES
  • SITE
  • LOG-IN
 

New Patent Eligibility Bill Takes Aim at High Court Inaction (1) – Bloomberg Law

3rd August 2022

  1. New Patent Eligibility Bill Takes Aim at High Court Inaction (1)  Bloomberg Law
  2. Tillis and Leahy introduce bipartisan legislation to improve patent quality  Vermont Biz
  3. Tillis’ Promised Patent Eligibility Bill Would Overrule Myriad, Mayo  IPWatchdog.com
  4. U.S. Senate bill would reform patent-eligibility standards  Reuters
  5. Senator Tillis Proposes Patent Eligibility Reform (Again) | McDonnell Boehnen Hulbert & Berghoff LLP – JDSupra  JD Supra
  6. View Full Coverage on Google News
 
 
 
 

OPUS IP on X (formerly Twitter)…

Twitter feed is not available at the moment.
 
 
 

RSS RECENT PATENT NEWS…

  • Firm Advises PepStar Therapeutics on Patent Matters Related to Acquisition of Inflammation Drug Program by Gilead Sciences - Wilson Sonsini
  • Asked & Answered with Baker Botts IP Litigator Doug Kubehl: Erasing a $847M Verdict and 30 Years in Dallas - The Texas Lawbook
  • Stellantis Patents A Secret Head-Up Display You'll Only Be Able To Access By Speeding - CarBuzz
  • AbbVie’s Dividend Survived Humira’s Patent Cliff. Will Merck and Amgen’s? - 24/7 Wall St.
 
 

RSS UK BUSINESS NEWS…

  • White House lifts tariffs on some Canadian goods as midterm elections loom
  • The little-known investment Martin Lewis wants you to understand...
  • Civil servant who juggled five jobs says he was 'surprised' to be charged with fraud
  • What is PHP and why did it spark a global cyber-security scramble?
 
 
 

Designed by Industrial Action

Copyright © 2026 OPUS IP Limited. All Rights Reserved

OPUS IP Limited: COMPANY & OTHER LEGAL INFORMATION